@article {7713,
	title = {Treatment of relapsed and refractory multiple myeloma in the era of novel agents},
	journal = {Cancer Treatment Reviews},
	volume = {37},
	year = {2011},
	note = {Cited By :46Export Date: 21 February 2017},
	month = {2011},
	pages = {266 - 283},
	abstract = {The introduction of the Immunomodulatory drugs (IMiDs) and proteasome inhibitors, used either as a single-agent or combined with classic anti-myeloma therapies, has improved the outcome for patients with relapsed myeloma. However, there is currently no generally accepted standard treatment for relapsed/refractory myeloma patients, partly because of the absence of trials comparing the efficacy of the novel agents in relapsed/refractory myeloma. Choice of a new treatment regimen depends on both patient and disease-specific characteristics. A lenalidomide-based regimen is the first choice in patients with neuropathy, while bortezomib has the highest efficacy in patients with renal insufficiency and is not associated with increased risk of thromboembolism. A second autologous stem cell transplantation (auto-SCT) can be applied in patients with a progression-free period of >=18-24. months after the first auto-SCT. In high-risk relapse such as occurring early after auto-SCT consolidation with allogeneic SCT can be considered. In this review we provide an overview of the various salvage regimens and give recommendations for treatment of patients with relapsed/refractory myeloma in different clinical settings. {\textcopyright} 2010 Elsevier Ltd.},
	keywords = {bortezomib, Guidelines, Lenalidomide, multiple myeloma, novel agents, Refractory disease, Relapse treatment, Thalidomide},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953125606\&doi=10.1016\%2fj.ctrv.2010.08.008\&partnerID=40\&md5=570ebf080c3ae8e2fb7d30fbfbfaeb1e},
	author = {Van De Donk, N.W.C.J. and Lokhorst, H.M. and Dimopoulos, M. and Cavo, M. and Morgan, G. and Einsele, H. and Kropff, M. and Schey, S. and Avet-Loiseau, H. and Ludwig, H. and Goldschmidt, H. and Sonneveld, P. and Johnsen, H.E. and Blad{\'e}, J. and San-Miguel, J.F. and Palumbo, A.}
}
